RxDoctor Payments Data

Keith Radbill, DO

Family Medicine · Merchantville, NJNPI 1861557795

Payments from drug & device makers

$12,355in general payments, 2019–2025

Across 142 payments — averaging $87.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$10K
  • Gilead$497
  • Braeburn Inc.$413
  • Indivior Inc.$266
  • Nevro Corp.$214
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$118
  • plus $479 from 16 others

What the payments were for

  • Consulting fees$9007%
  • Speaking & faculty fees$8,64070%
  • Travel & lodging$4103%
  • Food & beverage$2,40519%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,355 in reported general payments places this provider in the 95th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$139,131
Medicare patients
69
Services billed
1,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SublocadeBuprenorphine28$57,766
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl541$49,477
SuboxoneBuprenorphine Hcl/Naloxone Hcl43$28,457
ZubsolvBuprenorphine Hcl/Naloxone Hcl40$21,832
Buprenorphine Hcl23$492
Bupropion XlBupropion Hcl32$403
Duloxetine Hcl41$333
Buspirone Hcl32$282
Aripiprazole13$265
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine13$253
Gabapentin24$231
Risperidone25$142
Omeprazole14$135
Mirtazapine16$118
Fluoxetine Hcl26$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Sublocade, Suboxone$266$86,22471 claims
Orexo US, Inc.Zubsolv$83$21,83240 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Merchantville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →